Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Recruiting now Phase 3 NCT07181109
Run by Alnylam Pharmaceuticals · for 18 and older · All sexes
What this study is about
The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events. This is an event-driven study that will continue until the targeted number of positively adjudicated primary endpoint clinical outcome events (COEs) have been reached.
Who can join (things the study team will check)
✅ You may be able to join if…
- Is 18 years or older for patients with established cardiovascular disease (CVD)
- Is 55 years or older for patients with high risk for CVD
- Has established CVD (defined as coronary, cerebrovascular, or peripheral artery disease) or high risk for CVD
- Has treated hypertension on stable therapy with at least 2 standard of care antihypertensive medications, one of which must be a thiazide, thiazide-like, or loop diuretic
🚫 You may not be able to join if…
- Has known history of secondary hypertension
- Has symptomatic orthostatic hypotension
- Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3×upper limit of normal (ULN)
- Has total serum bilirubin >1.5×ULN
- Has international normalized ratio (INR) >1.5
- Has serum potassium >4.8 mEq/L
- Has estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m\^2
Where this trial is running
- Clinical Trial Site, Birmingham, Alabama, United States
- Clinical Trial Site, Birmingham, Alabama, United States
- Clinical Trial Site, Fairhope, Alabama, United States
- Clinical Trial Site, Foley, Alabama, United States
- Clinical Trial Site, Huntsville, Alabama, United States
- Clinical Trial Site, Huntsville, Alabama, United States
- Clinical Trial Site, Sheffield, Alabama, United States
- Clinical Trial Site, Chandler, Arizona, United States
- Clinical Trial Site, Gilbert, Arizona, United States
- Clinical Trial Site, Glendale, Arizona, United States
- Clinical Trial Site, Mesa, Arizona, United States
- Clinical Trial Site, Phoenix, Arizona, United States
+ 844 more sites.
Who to contact
Clinical Trial Information Line · 1-877-ALNYLAM · clinicaltrials@alnylam.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07181109.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.